Insulet (Nasdaq:PODD) announced today that it reshuffled its organizational structure to accelerate innovation and commercialization. In connection with the reorganization, Bret Christensen, EVP and chief commercial officer, leaves the company today to pursue other opportunities. He agreed to offer consulting services during a transition period. Jim Hollingshead, Insulet’s president and CEO, said Christensen “played an […]
Personnel Moves
Medtech veteran Tatyana Beldock joins Dyve Biosciences board
Dyve Biosciences announced today that Tatyana Beldock joined the company’s board of directors. Camarillo, California-based Dyve develops the DMAX delivery platform. Its transdermal drug delivery technology directly targets the acidic microenvironments that drive cancer cell growth and inflammation. “We are thrilled to have Tatyana join our board,” said Dr. Ryan Beal, CEO of Dyve. “Tatyana brings […]
RenovoRx appoints new SVP of clinical operations
RenovoRx (Nasdaq:RNXT) announced today that it appointed Leesa Gentry as senior vice president of clinical operations. Los Altos, California-based RenovoRx said Gentry brings with her “valuable leadership experience” to advance the company’s cancer treatment studies. She becomes the fourth addition to the company’s executive management team in the last year. That group includes COO Angela […]
Kindeva Drug Delivery names new chief commercial officer
Kindeva Drug Delivery announced today that it appointed David Stevens as its global chief commercial officer (CCO). Stevens’ role includes spearheading the commercial, business development and R&D activities for Kindeva. He aims to ensure continued growth, expansion and innovation from the drug delivery device contract development and manufacturing organization (CDMO). “David brings a breadth of […]
Endogenex taps former Medtronic executive as CEO
Endogenex, developer of a procedure for treating type 2 diabetes, announced today that it appointed Stacey Pugh as its new CEO. Pugh’s responsibilities at Minneapolis-based Endogenex include expanding the company’s clinical initiatives evaluating its ReCET procedure. ReCET — a novel, endoscopic, outpatient procedure — targets the underlying cellular abnormalities in the duodenum. These abnormalities contribute […]
Know Labs establishes scientific advisory board to advance non-invasive glucose monitoring
Know Labs (NYSE:KNW) announced today that it established a scientific advisory board to accelerate development for its glucose monitoring devices. Seattle-based Know Labs expects the members to advise on algorithm refinement, device development, clinical trial design and research publication strategy. They’ll work alongside the company’s current medical and regulatory advisory board members. Know Labs develops […]
Vaccine patch maker Vaxess names former Sanofi exec as chief strategy officer
Vaxess Technologies, developer of a shelf-stable vaccine patch, announced today that it named Steve Bende as its new chief strategy officer. Bende previously served as global head of new products at Sanofi Pasteur. He led international, multifunctional teams at the pharmaceutical giant. That included assessing the commercial viability of potential new products. Prior to Sanofi, […]
Tandem Diabetes Care appoints new board chair
Tandem Diabetes Care (Nasdaq:TNDM) recently announced the appointment of Rebecca Robertson as the chair of its board of directors. Robertson initially joined Tandem’s board as an independent director in January 2019. She succeeds Kim Blickenstaff as chair. Blickenstaff intends to continue as a member of the board. “We’re deeply grateful to Kim for his instrumental […]
Glucose monitor maker Know Labs names new CEO, makes other executive changes
Know Labs (NYSE:KNW) announced that it named Ron Erickson as CEO as the company makes a handful of changes at the top. The Seattle-based non-invasive glucose monitor maker’s board unanimously named Erickson, its founder and chair, as CEO. Former CEO Phil Bosua stepped down as an executive officer of the company and board member. Know […]
Dexcom appoints former J&J exec as CCO, sets 2023 guidance
Dexcom (Nasdaq:DXCM) announced today that it appointed Teri Lawver to its newly created role of chief commercial officer (CCO). Lawver’s position oversees the global commercial organization at the continuous glucose monitoring (CGM) technology developer. She holds responsibility for global sales, marketing and customer experience. Before joining San Diego–based Dexcom, Lawver spent two decades in a […]
